Moderna Inc (NASDAQ: MRN) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program. The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target. The Moderna Thesis: There is good probability the vaccine will work…
You don't have permission to access "http://www.medpagetoday.com/neurology/alzheimersdisease/120668" on this server. Reference #18.2c153b17.1775512948.a208d49 https://errors.edgesuite.net/18.2c153b17.1775512948.a208d49
Millions of Americans are taking GLP-1 agonist medications like Ozempic, Wegovy, and Zepbound to lose weight, treat type 2 diabetes, and manage other chronic health conditions. And while these drugs are generally really effective, they can also bring on some not-so-great side effects, including a big drop in muscle mass for some people. Losing muscle
Four companies control about 80 percent of the U.S. beef market, and there is no reason to believe that any of them are satisfied with their share. Published: April 05, 2026, 8:00 am The USDA’s Food Safety and Inspection Service (FSIS) reported that Listeria monocytogenes was the most frequent cause of outbreaks it investigated during fiscal year